Dealmakers Conversations

As CEO and co-founder of Kytopen, Paulo is leading the development & commercialization of their proprietary Flowfect™ technology for non-viral delivery of molecules into hard-to-transfect immune cells. He co-invented the Flowfect™ technology during his postdoc (Research Scientist) in the Mechanical Engineering department at MIT. The scalable Flowfect™ technology combines microfluidics and automation to make this process easier, faster, and more reliable. With this automated cell engineering platform they plan to enable new discoveries in biology that will lead to cost-effective cell and gene therapies.